Recon: Novartis to buy RNA developer Avidity in $12B deal; Intellia halts gene therapy trials following patient liver injury
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsProduct LifecycleUnited States